

Scientific Seminar Agenda

TUESDAY 5 DECEMBER

13:15 Delegate registration and welcome coffee

14:00 – 16:00

EFFECTIVENESS PREDICTION/MODELLING FOR DECISION-MAKING

CHAired BY: **DR. BILLY AMZAL**

14:15 **Value of eHCD for effectiveness evaluations**

Prof. Tjeerd van Staa, *Professor of Health eResearch*, University of Manchester

14:40 **Efficacy to effectiveness modelling: From ad hoc to standardised approaches**

Dr. Hélène Karcher, *VP, Global Head of RW Modelling*, analytica|LASER

15:05 **The use of effectiveness predictive modelling in health economic evaluation for NICE decisions: Lessons learnt and current trends**

Prof. Richard Grieve, *Professor of Health Economics Methodology*, LSHTM/NICE

15:30 **Roundtable and closing remarks**

Prof. Stephen Evans, *Professor of Pharmacoepidemiology*, LSHTM/PRAC

16:00 Networking coffee break

16:30 – 18:10

EFFECTIVENESS MEASUREMENT FOR DECISION-MAKING

CHAired BY: **PROF. STEPHEN EVANS**

16:30 **Application of lessons from risk assessment with pharmacoepidemiologic methods to the assessment of real-life benefit and performance**

Prof. Bernard Begaud, *Professor of Pharmacology*, Bordeaux University

16:55 **Case study: The Salford Lung Study (SLS) in the UK**

Dr. Sue Collier, *Physician Lead Translational Medicine*, GSK

Loretta Jacques, *Clinical Development Director and SLS Project Leader*, GSK

17:20 **Big data vs. deep data analytics: How to combine sensitivity and specificity of eHCD and clinical pharmaco-epidemiology for public health decision-making**

Dr. Lamiae Grimaldi, *Senior Global Scientist*, analytica|LASER/LSHTM

17:45 **Roundtable and closing remarks**

Dr. Billy Amzal, *Scientific Vice President*, analytica|LASER

Executive Forum Agenda

WEDNESDAY 6 DECEMBER

- 8:15 Delegate registration — welcome tea and coffee
- 9:00 **Opening and orientation for the day**
Prof. Lucien Abenhaim, LSHTM, analytical LASER, and former member of the Executive Board of WHO

MORNING WORLD CHALLENGES

- 9:10 **Accessibility to innovative medicines: Lessons from the past & challenges for the future**
Prof. Peter Piot, *Director*, London School of Hygiene & Tropical Medicine (LSHTM)
- 9:30 **Keynote address: Executive views on access and accessibility**
Dr. Olivier Brandicourt, *Chief Executive Officer*, Sanofi
- 10:00 **The world's situation for the access to medicines**
Dr. Sarah Garner, World Health Organization
- 10:20 **Bringing the patients' voice to the value discussion**
Dr. Kaisa Immonen, European Patients' Forum
- 10:35 Morning break
- 10:55 **Fostering value in the era of personalised medicine in the US**
Dr. Harold L. Paz, *Executive Vice President & Chief Medical Officer*, Aetna, US
- 11:20 **Is high-value innovation affordable in Europe?**
Prof. Gerard de Pouvourville, *Chair of Health Economics*, ESSEC Business School
- 11:45 **PANEL DISCUSSION**
Accessibility to patients and affordability to health systems
MODERATOR AND INTRODUCTION OF THE DISCUSSION:
Prof. Dominique Le Guludec, *President*, HAS (French Higher Health Authority)
- All session speakers join panel*
- 12:25 Lunch break

AFTERNOON I EUROPEAN HTA DECISION-MAKING

- 13:40 **EUnetHTA: Europe at a turning point?**
Dr. Wim Goettsch, *Chair, Executive Board*, EUnetHTA
- 13:55 **Managing access to innovation in the English NHS**
Sir Andrew Dillon, *Chief Executive*, National Institute for Health and Care Excellence, UK
- 14:15 **The context of access to innovation in France**
Dr. Chantal Bélorgey, *Head of Evaluation*, HAS (French Higher Health Authority)
- 14:30 **Did 5 years of change in Germany prepare for the new accessibility challenges?**
Dr. Regina Skavron, G-BA, The Federal Joint Committee, Germany

14:45 **Access to highly innovative therapies in CEE countries: The example of Croatia**
Dr. Mirjana Huić, Agency Quality and Accreditation in Health Care and Social Welfare, Croatia

15:00 **The Italian experience**
Dr. Giovanna Scroccaro, *Pricing and Reimbursement Committee*, AIFA, Italy

15:15 **STAKEHOLDER ROUNDTABLE**

Are today's HTA value models up to the innovation challenge?

MODERATOR:

Dr. Wim Goettsch, *Chair, Executive Board*, EUnetHTA

DISCUSSANTS:

Dr. Ansgar Hebborn, *Global Head, Payer and HTA Policy*, Roche and *Chairman of EFPIA HTA Group*; Dr. Alric Rüther, *Head of International Affairs*, IQWiG, Germany

All session speakers join panel

16:00 Afternoon break

AFTERNOON II

CHALLENGES IN TARGETED THERAPIES AND RARE DISEASES

16:15 **The challenges in developing accessible, highly innovative therapies**
Dr. Stephen Moran, *Global Head of Strategy*, Novartis

16:40 **Social willingness to pay: An alternative method for valuation?**
Prof. Michael Schlander, University of Heidelberg, *Head of Health Economics* at the German Cancer Research Center (DKFZ); *Chairman*, Institute for Innovation & Valuation in Health Care

17:00 **Looking for a 'new deal' for access to therapy for rare diseases**
Yann Le Cam, *CEO*, Eurordis Rare Diseases Europe

17:20 **ROUNDTABLE DISCUSSION**

MODERATOR:

Prof. Peter Piot, *Director*, LSHTM; *Founder and former Head UNAIDS*, United Nations

DISCUSSANT:

Adrian Griffin, *VP, Head of HTA & Reimbursement Policy*, Johnson & Johnson

All session speakers join panel

17:45 **CONCLUDING REMARKS**

Prof. Peter Piot and Prof. Lucien Abenheim, LSHTM